Truist Securities Maintains Buy on Insmed, Raises Price Target to $88
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has maintained its Buy rating on Insmed (NASDAQ:INSM) and raised the price target from $68 to $88, indicating strong confidence in the company's future performance.
July 01, 2024 | 12:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities has maintained its Buy rating on Insmed and raised the price target from $68 to $88, indicating strong confidence in the company's future performance.
The raised price target from $68 to $88 by Truist Securities suggests a positive outlook for Insmed's future performance. This is likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100